<DOC>
	<DOCNO>NCT02643407</DOCNO>
	<brief_summary>To compare efficacy safety docetaxel plus nedaplatin docetaxel plus cisplatin managment advanced/relapsed squamous cell lung cancer .</brief_summary>
	<brief_title>Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel Treatment Advanced/Relapsed Squamous Cell Lung Cancer</brief_title>
	<detailed_description>This study prospective evaluate whether efficacy safety docetaxel plus nedaplatin non-inferior docetaxel plus cisplatin managment advanced/relapsed squamous cell lung cancer .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Nedaplatin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Patients require 18 75 year , histologically cytologically proven squamous cell carcinoma lung , stage ⅢB ( unfit definitive radiotherapy ) , stage Ⅳ relapsing ; 2 . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) zero one ; 3. life expectancy &gt; 3 month ; 4 . No previous history malignancy ( except adequately treat carcinomainsitu cervix basal cell carcinoma skin superficial bladder cancer [ Ta , Tis &amp; T1 ] ) ; previously untreated chemotherapy ( eg . gemcitabine , platinum , paclitaxel ) ; previously systemic therapy locally advance metastatic disease ; patient eligible participation study recurrence metastasis become locally advanced metastatic lung cancer 12 month treatment gemcitabine , platinum paclitaxel regimen adjuvant neoadjuvant chemotherapy ; 5 . Adequate organ function require , evidence absolute neutrophil count ≥ 1.5 x 109 /L , platelet count ≥ 100 x109/L , hemoglobin ≥ 90 g/L ( 9 g/dL ) ; 6. hepatic enzyme level ≤ 2.5 x upper limit normal range ( ULN ) , alkaline phosphatase level ≤ 5.0 x ULN , total bilirubin level ≤ 1.5 x ULN , serum creatinine level ≤1.5 mg/dL ( creatinine clearance ≥50 mL/min ) ; 7 . Previous radiotherapy allow involved &lt; 25 % bone marrow complete 4 week study entry ; Patients must recover acute toxicity clinical trial ; 8 . Pregnancy test : negative ( female ) ; Women fertility need pregnancy test ( serum urine ) 7 day enter group result negative . Male female patient reproduction potential use approve contraceptive method 8 week end study treatment . 9 . Patients judge researcher compliance research requirement followup . 10 . All patient provide write informed consent enrollment . 11 . The standard firstline platinumbased regimen accord clinical practice , efficacy evaluate every two cycle . 1 . EGFR positive ALK positive ( patient , status EGFR ALK unknown due detection , include ) ; 2 . Participation clinical research 4 week first dosage , except non interventional epidemiological investigation ; 3 . Patients complication high risk ; 4 . Primary brain tumor central nervous system ( CNS ) metastatic carcinoma . The patient suspect CNS metastatic carcinoma scan 28 day enter group . Other malignant disease five year ago ( except conebiopsied carcinomainsitu cervix adequately treat basal squamous cell carcinoma skin ) 5 . Thirdspace fluid collection clinical significance , ascites pleural effusion , control drainage method ; 6 . Serious mental retardation cognitive impairment , psychotic illness , poor compliance , meet narrate therapy responder ; 7 . No eliminated acute chronic infection , serious concomitant disease ; 8 . Serious uncontrolled concomitant disorder ( active infection , ischemic heart disease , arrhythmia , liver dysfunction , peripheral nerve disorder ) ; 9 . Patients bleed tendency organ transplant ; 10 . Alcohol drug dependent patient ; patient chronic administration adrenal cortical hormone immunosuppressive ; patient AIDS infectious disease ; 11 . Active hepatitis , liver metastasis 3/4 whole liver ; 12 . A history drug allergy ; 13 . The female patient reproductive year unwilling contraception ; 14 . Accept antitumor therapy time ; 15 . The researcher believe patient able complete entire clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>squamous cell carcinoma</keyword>
	<keyword>nedaplatin</keyword>
	<keyword>cisplatin</keyword>
	<keyword>docetaxel</keyword>
</DOC>